| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
7H-Purine-2,6-diamine is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification in drug discovery. It does not have a defined primary pharmacological target as a fragment molecule. 2,6-Diaminopurine is a compound used for studying leukemia. Its derivatives may target various biological targets depending on the specific modifications made.
|
|---|---|
| ln Vitro |
2,6-Diaminopurine is a substance that's studied leukemia.
In vitro studies have shown that 2,6-Diaminopurine is a compound used for studying leukemia. The compound is a fragment molecule that provides a structural basis for the design and screening of novel drug candidates. In research settings, it is used as a building block for synthesizing libraries of purine-based compounds that are subsequently screened for biological activity. |
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for 7H-Purine-2,6-diamine as a therapeutic agent. The compound is used as a fragment molecule and building block in drug discovery. It is not administered directly to animals. Its derivatives and the compounds synthesized from it may be evaluated in animal models depending on the therapeutic area.
|
| Enzyme Assay |
For non-cellular assays, 7H-Purine-2,6-diamine is characterized by standard analytical techniques including NMR, HPLC, and mass spectrometry to confirm identity and purity. Purity: >98.0%. The compound has a molecular weight of 150.14 and molecular formula C₅H₆N₆. Storage: keep in a cool, dry place protected from light and moisture. Typical protocols involve using the compound as a building block in organic synthesis.
|
| Cell Assay |
For in vitro cell-based studies, 7H-Purine-2,6-diamine is not typically used as a direct test compound. It is a fragment molecule and building block for synthesizing biologically active molecules that are subsequently tested in cell-based assays. If handled in a biological laboratory context, standard safety precautions should be taken.
|
| Animal Protocol |
For in vivo animal studies, 7H-Purine-2,6-diamine is not administered directly as a test compound. It is used in chemical synthesis to produce pharmaceutical candidates that are subsequently evaluated in animal models. The compound can be formulated using standard injection vehicles if required for specific research protocols.
|
| ADME/Pharmacokinetics |
7H-Purine-2,6-diamine has a molecular weight of 150.14 and molecular formula C₅H₆N₆. Purity: >98.0%. Storage: keep in a cool, dry place protected from light and moisture. The compound is a solid at room temperature. Solubility: soluble in common organic solvents. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
7H-Purine-2,6-diamine is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD₅₀ values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
9H-purine-2,6-diamine is a type of 2,6-diaminopurine compound with the structure 9H-purine, where the hydrogen atoms at positions 2 and 6 are replaced by amino groups. It possesses antitumor activity. It is a primary amino compound belonging to the 2,6-diaminopurine class. Its function is similar to adenine. 2,6-Diaminopurine is one of many organic compounds with similar purine structures, which exhibit antiviral and antitumor properties. 2,6-Diaminopurine nucleoside is a universal precursor for the synthesis of antiviral and antitumor drugs with specific N-6 position modifications. (NCI04)
7H-Purine-2,6-diamine (CAS 1904-98-9) is also known as 2,6-diaminopurine and 2-aminoadenine. It is a fragment molecule that serves as an important scaffold for drug discovery. 2,6-Diaminopurine is a compound used for studying leukemia. No clinical trials or therapeutic approvals exist. |
| Molecular Formula |
C5H6N6
|
|---|---|
| Molecular Weight |
150.14
|
| Exact Mass |
150.065
|
| CAS # |
1904-98-9
|
| Related CAS # |
7280-83-3 (sulfate);22194-11-2 (lactate salt/solvate)
|
| PubChem CID |
30976
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
749.0±63.0 °C at 760 mmHg
|
| Melting Point |
117-122 °C(lit.)
|
| Flash Point |
447.8±20.9 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.940
|
| LogP |
-0.21
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
150
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1([H])C([H])=NC2C1=C(N([H])[H])N=C(N([H])[H])N=2
|
| InChi Key |
MSSXOMSJDRHRMC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H6N6/c6-3-2-4(9-1-8-2)11-5(7)10-3/h1H,(H5,6,7,8,9,10,11)
|
| Chemical Name |
7H-purine-2,6-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6605 mL | 33.3023 mL | 66.6045 mL | |
| 5 mM | 1.3321 mL | 6.6605 mL | 13.3209 mL | |
| 10 mM | 0.6660 mL | 3.3302 mL | 6.6605 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
